Turn Bio Acquires ARMMs Technology,Advancing Precision Epigenetic Therapies Mountain View,California,March 27,2025 – Turn Biotechnologies,a leader in epigenetic reprogramming,has announced teh acquisition of ARMMs technology (Arrdc1-mediated microvesicles),marking a significant leap forward in targeted drug delivery and regenerative medicine. This acquisition promises to expand the scope and precision of Turn Bio’s epigenetic therapies, offering new hope for … Read more
You can read the full story here: Turn Biotechnologies Acquires Vesicular Arms: Pioneering Epigenetic Reprogramming Therapies .
